GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026. Phase 1 protocol allows multiple solid tumor types known to express B7-H3. Unaudited proforma cash balance as of January 31, 2026, of approximately $9 million anticipated to extend cash runway through Q4 2026. SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary TriKE® natural killer (NK) cell engager platform, today announced FDA clearance of its IND application for GTB-5550, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to initiate in mid-2026. “FDA clearance of our third TriKE® IND, GTB-5550, represents a defining moment for GT Biopharma as we bring another NK cell engager into the clinic,” said Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma.
This excerpt is quoted from the original release. Read the full announcement on GlobeNewsWire.
Brief Summary
GT Biopharma, Inc. (NASDAQ: GTBP) has received FDA clearance for its IND application for GTB-5550 TriKE®, marking a crucial step forward in their immuno-oncology initiatives. This clearance allows the company to move forward with a Phase 1 clinical trial expected to begin in mid-2026.
- FDA Clearance for GTB-5550 IND application.
- Initiation of Phase 1 trial slated for mid-2026.
- Multi-tumor type protocol targeting B7-H3 expression.
- Approx. $9 million cash runway projected through Q4 2026.
Why it matters: This clearance positions GT Biopharma favorably in the expanded immuno-oncology landscape, providing new opportunities for solid tumor treatments.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by GlobeNewsWire on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.